Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDP1066
- Development stage
- Discontinued
- Lead developer
- Evelo Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EDP1066 is an investigational **orally administered monoclonal microbial** therapy from Evelo Biosciences being developed as an oral biologic for inflammatory disease. Public clinical-trial records describe it as a single-strain, non-genetically modified microbial product delivered in capsules and evaluated in a first-in-human Phase 1a/1b randomized, double-blind, placebo-controlled study in healthy volunteers and in patients with mild to moderate psoriasis and atopic dermatitis. Its intended pharmacology appears to be **immunomodulation via host-microbe interactions in the small intestine**, consistent with Evelo's monoclonal microbial platform, but the exact molecular target and target-level mechanism were not explicitly identified in the provided sources. The program was publicly associated with Evelo's inflammatory disease pipeline and manufacturing arrangements with Sacco for oral delivery of single-strain microbes.
Beyond the preview
Go deeper on EDP1066.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDP1066.